X-ray computed tomography (CT) and magnetic resonance (MR) imaging are essential tools in modern medical diagnosis and treatment. However, traditional contrast agents are inadequate in the diagnosis of various health conditions. Consequently, the development of targeted nano-contrast agents has become a crucial area of focus in the development of medical image-enhancing contrast agents. To fully understand the current development of nano-contrast agents, this review provides an overview of the preparation methods and research advancements in CT nano-contrast agents, MR nano-contrast agents, and CT/MR multimodal nano-contrast agents described in previous publications. Due to the physicochemical properties of nanomaterials, such as self-assembly and surface modifiability, these specific nano-contrast agents can greatly improve the targeting of lesions through various preparation methods and clearly highlight the distinction between lesions and normal tissues in both CT and MR. As a result, they have the potential to be used in the early stages of disease to improve diagnostic capacity and level in medical imaging.
Background: Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low response rates and immune‐related adverse events (irAEs), currently restrict their clinical application. Were these disadvantages to be overcome, more patients could derive prolonged benefits from ICIs. At present, many basic experiments and clinical studies using hyperthermia combined with ICI treatment (HIT) have been performed and shown the potential to address the above challenges. Therefore, this review extensively summarizes the knowledge and progress of HIT for analysis and discusses the effect and feasibility.Methods: In this review, we explored the PubMed and clinicaltrials.gov databases, with regard to the searching terms “immune checkpoint inhibitor, immunotherapy, hyperthermia, ablation, photothermal therapy”.Results: By reviewing the literature, we analyzed how hyperthermia influences tumor immunology and improves the efficacy of ICI. Hyperthermia can trigger a series of multifactorial molecular cascade reactions between tumors and immunization and can significantly induce cytological modifications within the tumor microenvironment (TME). The pharmacological potency of ICIs can be enhanced greatly through the immunomodulatory amelioration of immunosuppression, and the activation of immunostimulation. Emerging clinical trials outcome regarding HIT have verified and enriched the theoretical foundation of synergistic sensitization.Conclusion: HIT research is now starting to transition from preclinical studies to clinical investigations. Several HIT sensitization mechanisms have been reflected and demonstrated as significant survival benefits for patients through pioneering clinical trials. Further studies into the theoretical basis and practical standards of HIT, combined with larger‐scale clinical studies involving more cancer types, will be necessary for the future
1 January 2021 in International Journal of Pharmaceutics
Background: The development of paclitaxel-resistance led to the tumor relapse and treatment failure of non-small cell lung cancer. Shikonin has been demonstrated to show anti-cancer activity in many cancer types. The present study aimed to investigate the anti-cancer activity of shikonin in paclitaxel-resistant non-small cell lung cancer treatment. Methods: MTT, clonogenic assay, apoptotic cell death analysis, western blot, qRT-PCR, gene knockdown and overexpression, xenograft experiment, immunohistochemistry were performed. Results: Shikonin decreased paclitaxel-resistant NSCLC cell viability and inhibited the growth of xenograft tumor. Shikonin induced apoptotic cell death of paclitaxel-resistant NSCLC cell lines and suppressed the level of NEAT1 and Akt signaling of paclitaxel-resistant NSCLC cell lines and xenograft tumors. Either low dose or high dose of shikonin considerably suppressed the cell growth and induced the cell apoptotic death in NEAT1 knockdown A549/PTX cells, and p-Akt expression was decreased. Conclusions: Shikonin could be a promising candidate for paclitaxel-resistant NSCLC treatment.
In this paper, a new dual-polarized (DP) omnidirectional hemisphere dielectric resonator antenna (DRA) for wireless capsule endoscope system (WCE) is proposed. The antenna was excited in its omnidirectional TM018 and TE018 modes to radiate DP wave by a feeding probe and arc microstrip line, respectively. Omnidirectional DP wave can be obtained when the TM018 and TE018 mode are equal in amplitude and phase. The TM018 mode that is equivalent to electric dipole can be obtained by probe feeding. The TE018 mode is excited by four arc microstrip lines feeding. They provide a pair of equivalent magnetic dipoles that are orthogonal to TM018 mode. The DP omnidirectional DRA be fabricated without the need of feed network than circularly polarized. The WCE and the human body equivalent tissue model are adopted in simulation. Water is equivalent to gastric juice during measurement. Communication links between the proposed capsule antenna and the external receiving antenna are measured to demonstrate the advantages the DP brings when capsule antenna is placed in different orientations. The capsule endoscope system with different antennas is placed in water to measure receiving power. The measurement shows that the fabricated antenna exhibits a wide impedance bandwidth for S11 <; -10 dB (2.4-2.48 GHz). The radiation efficiency of the antenna is between 15-18%, and the peak gain is between -13.5 and -15dBi.